



LYKA LABS LIMITED

CIN: L24230GJ1976PLC008738

Registered Office: 4801 / B & 4802 / A, GIDC Industrial Estate, Ankleshwar, Gujarat, 393 002.

Corporate Office: Ground Floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai 400 036.

Website: www.lykalabs.com; Email: companysecretary@lykalabs.com

CORRIGENDUM TO THE NOTICE OF EOGM

We draw attention of all the Members of Lyka Labs Limited (the 'Company') that an **Extraordinary General Meeting** (the 'EOGM') of the Company is scheduled on **Friday, 17th February 2023, at 11.00 a.m.** through Video Conferencing ('VC') to transact the businesses mentioned in the Notice convening the EOGM dated 21st January 2023 (the 'EOGM Notice').

The Company had on 24th January 2023, completed dispatch of EOGM Notice through emails to those Members whose names appeared in the Statement of Beneficial Ownership maintained by National Securities Depository Limited (the 'NSDL') and Central Depository Services (India) Limited (the 'CDSL') or Register of Members of the Company.

The Members of the Company are requested to take note of the following additional information / disclosure in the EOGM Notice under point (c) of the Explanatory Statement under the head "**Basis on which the price has been arrived at**":

Since it is proposed to issue more than 5% of the fully diluted post issue capital to the proposed allottee, i.e. Ipca Laboratories Limited, in accordance with Regulation 166A(1) of the SEBI (ICDR) Regulations, 2018, a Report dated February 3, 2023 from M/s Perch Valuation LLP a IBBI registered valuer with Registration Number : IBBI/RV-E/06/2022/173 has also been taken wherein the valuer has concluded the fair value of the shares of the company at Rs.138.14 per Equity Share. The preferential issue price is more than the price arrived at in the Valuation Report. The Valuation Report is available on our website at www.lykalabs.com and also will be placed before the Members during the EOGM. We also confirm that the Articles of Association do not contain any restrictive provision.

Members of the Company are also requested to note that following additional disclosure in the EOGM Notice under point (m) of the Explanatory Statement immediately after the para "Undertaking":

Neither the Company nor any of its Promoters and Directors is a willful defaulter or a fraudulent borrower.

All other information and content as set out in the EOGM Notice dated 21st January 2023 including the resolutions to be considered thereat remain unchanged. The Members may note that the EOGM Notice and the Corrigendum to the EOGM Notice will also be available on the Company's website www.lykalabs.com and on website of the Stock Exchanges at www.bseindia.com and www.nseindia.com.

This corrigendum to the EOGM Notice shall form an integral part of the EOGM Notice dated 21st January 2023, which has already been circulated to the Members of the Company. Accordingly, all the concerned Members, Stock Exchanges, Depositories, Registrar and Share Transfer Agent, agencies appointed for e-voting, other authorities, regulators and all other concerned persons are requested to take note of the aforesaid corrigendum.

For Lyka Labs Limited

Kishore P. Shah

Company Secretary & Compliance Officer

Mumbai; 7th February 2023.